Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
In a new publication, researchers from the German Center for Diabetes Research (DZD) and the University of Medicine ...
Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...
The placebo-controlled, double-blind, randomised Phase I trial involved 100 healthy participants.
Licensed scientific and clinical intelligence integrated into the 3RnD platform to support AI-Driven Discovery and ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial ...
A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027. Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be rep ...
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support ...
Clinical Trials Arena on MSN
From real to regulatory: why RWD needs trial-grade standards
Jen Lamppa, VP of Commercial Strategy at Inovalon, says that RWD will be held to the same scrutiny as trial data if used in regulatory submissions.
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for ...
Frees sites from duplicate data entry and connects EHR and EDC for higher quality trial data, fasterPLEASANTON, Calif., Jan. 29, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results